Teva (TEVA) and Antares (AIS) Announce FDA Approval of Needle-Free Injector for Tev-Tropin(R)
More News related to AIS
- Trading Radar for 11/09: Dish Network (DISH), Rockwell (ROK), Priceline.com (PCLN), MBIA (MBI), Ticketmaster (TKTM) Report
- Antares Pharma to Present at the Merriman Investor Summit 2009
- Antares Pharma to Host Third Quarter 2009 Earnings Call
- Antares Pharma to Present at the 20th Annual Oppenheimer Healthcare Conference
- Teva (TEVA) and Antares (AIS) Announce FDA Approval of Needle-Free Injector for Tev-Tropin(R)
More News related to TEVA
- Trading Outlook for Novavax Inc. Issued by InvestorSoup.com
- Teva Pharmaceutical (TEVA) Announces Commercial Launch of Generic Allegra-D
- Teva Introduces Fexofenadine HCl and Pseudoephedrine HCl Extended-Release Tablets; An Alternative to Allegra-D(R) 12 Hour Tablets
- Teva Pharma (TEVA) Guides FY09, FY10 Inline With the Street
- Teva Pharma (TEVA) Posts Q3 EPS of $0.89, Beats by 1c
Earlier this morning, Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) and its partner, Antares Pharma, Inc. (Amex: AIS) today announced the approval of a Supplemental New Drug Application, which added "needle-free injection" to its Tev-Tropin(R) [somatropin for injection] brand human growth hormone drug label. Teva will market the Antares needle-free device as the Tev-Tropin Tjet Injector system.
Shares of Antares have spiked about 60% on the news today. The stock is seeing extremely heavy volume: already has more than 9.5 million shares, which compares to its 30-day average volume of 157,000 shares.
Related Categories
Corporate NewsStocks Mentioned
-0.01
+0.41Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
what is this? ais at $25.12???
Ross D on Jul 4, 2009 05:25 PMis this for real? not even funny if not!